Abstract
Background: Amitriptyline hydrochloride is a Tricyclic Antidepressant (TCA) belonging to BCS class I exhibiting only 30-60% bioavailability and often coupled with poor patient compliance. The primary objective was to develop a formulation with commercial viability and reduced dosing frequency in order to promote adherence of depressed patients to the treatment regime. The study also focused on reducing the dose of amitriptyline by controlling the release using osmotic technology, thereby reducing the side effects of amitriptyline.
Methods: Controlled Porosity Osmotic Pump (CPOP) systems eliminate the need for expensive drilling processes and are apt for industrial manufacturing systems, whereas other osmotic systems have practical limitations. The wet granulation technique was used to formulate CPOP tablets of amitriptyline as burst release was observed in directly compressed tablets. Screenings of polymers, osmogen and weight gain were performed.
Results: F6-D3 (3 % Di-butyl phthalate) was optimized with lactose as osmogen and HPMC K 35 M as polymer. The drug release from the optimized formulation was independent of the effect of agitational intensity and pH. The osmotic pressure of the dissolution medium was increased to confirm the osmotic release mechanism. The drug release decreased markedly due to an increase in osmotic pressure.
Conclusion: Accelerated Stability studies were carried out in ICH-certified stability chambers as per the specifications and were found stable. It was evident that osmotic pressure generated within the CPOP tablets along with the controlled formation of pores using Cellulose Acetate (CA-398-10 NF/ EP) was able to control the release of amitriptyline hydrochloride for 24 hours. Thus, the Oral Osmotic Drug Delivery system is a promising technology for product life-cycle strategies.
Keywords: Antipsychotics, tricyclic antidepressants, controlled porosity osmotic pump (CPOP) tablets, cellulose acetate, cellulose acetate (CA-398-10 NF / EP), osmogen.
[http://dx.doi.org/10.18433/J38W25] [PMID: 21486532]
[http://dx.doi.org/10.1192/bjp.178.2.129] [PMID: 11157426]
[http://dx.doi.org/10.1208/s12249-010-9468-y] [PMID: 20582493]
[http://dx.doi.org/10.3109/03639045.2010.546403] [PMID: 21231888]
[http://dx.doi.org/10.4314/tjpr.v8i3.44541]
[http://dx.doi.org/10.1208/pt0803053] [PMID: 17915803]
[http://dx.doi.org/10.4103/0976-0105.109398] [PMID: 24808662]
[http://dx.doi.org/10.1016/j.ijpharm.2006.03.020] [PMID: 16621361]
[PMID: 25657794]
[http://dx.doi.org/10.12991/mpj.20162040694]
[http://dx.doi.org/10.1016/j.ijpharm.2006.09.038] [PMID: 17052871]
[http://dx.doi.org/10.1002/jps.2600641218] [PMID: 1510]
[http://dx.doi.org/10.1208/pt050471] [PMID: 15760068]
[http://dx.doi.org/10.3109/03639049709150490]
[http://dx.doi.org/10.1208/pt040331] [PMID: 14621963]
[http://dx.doi.org/10.1016/S0031-6865(97)00007-1]
[http://dx.doi.org/10.1021/js9800026] [PMID: 9607950]
[http://dx.doi.org/10.1081/DDC-100101287] [PMID: 10872087]
[http://dx.doi.org/10.1016/0168-3659(86)90004-0]
[http://dx.doi.org/10.1081/DDC-120003001] [PMID: 12056533]